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No Evidence of Long-Term Immunosuppression after 
High-Titer Edmonstron-Zagreb Measles Vaccination in 
Senegal 
Colleagues-In measles vaccine trials in Guinea-Bissau [I], 
Senegal [2], and Haiti [3], girls who received high-titer Edmon- 
ston-Zagreb (EZ; > lo4-' infectious particles) or Schwarz measles 
vaccines at 4-6 months of age had a higher mortality than girls 
receiving standard measles vaccine at 9-10 months of age. An 
explanation of this surprising observation, which was not due to 
insufficient protection against measles [2,4, 51, is important for 
the future development of measles vaccines and measles con- 
trol. We and others [3] thought that high-titer measles vaccine 
could mimic natural measles, inducing immunosuppression 
with subsequent susceptibility to other infections. Thus, like 
others in Guinea-Bissau [6] and Peru [7], we undertook an im- 
munologic examination ofa subsample of 143 children who had 
received high-titer EZ or standard-titer Schwarz measles vac- 
cines. Little is known about the best predictors of immunocom- 
petence among children in developing countries, so we used 
several different tests with the objectives of finding immuno- 
logic differences between the vaccine groups and identifying 
possible defects that could be corrected through specific inter- 
ventions (e.g., vitamin A supplementation or nutritional rehabil- 
itation). 
The study was camed out in Niakhar, Senegal, a rural area 
with a population of -26,000 [2]. The trial ofhigh-titer vaccine 
included all children bom to resident mothers between Febru- 
ary 1987 and January 1989 [2]. There were 73 children who had 
received EZ vaccine at 5 months and 70 children who had re- 
ceived placebo at 5 months and standard Schwarz vaccine at 1 O 
months who were selected at random from the children residing 
in the study area in the fall of 1991 when the children were 
36-44 months old. The children were visited at home three 
times. At the first visit, the children were examined anthropo- 
metrically, had a venous blood sample collected, and were vacci- 
nated with diploid rabies vaccine lot El227 (Institut Mérieux, 
Lyon, France). Rabies vaccine was selected as a potentially ben- 
eficial immunization that none of the participants were likely to 
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have encountered already. During the first visit, skin tests with 
tuberculin purified protein derivative (PPD) and candida anti- 
gens were also applied; indurations of 3 2  mm at the reading 2 
days later were considered positive [7]. The children received 
the second dose of rabies vaccine 4 weeks after the first visit. At 
the last visit, 2 months later, a fingerprick blood sample was 
obtained for the determination of rabies antibodies (Platelia 
ELISA, Diagnostic Pasteur, Marnes-la-Coquettes, France). 
At enrollment at 5 months of age, there was no difference in 
maternal measles antibody levels or nutritional status between 
the 143 children in the immunologic study and the other 1436 
children in the trial. At the time of the immunologic study in 
199 I ,  there were no differences between the EZ and Schwarz 
groups with respect to weight for age, height for age, or weight 
for height. Other results from the study are reported in table 1. 
Though there were no differences overall, more consultations at 
a health center or hospital were reported for girls who had re- 
ceived EZ (47%) than for those who had received standard 
Schwarz vaccine (24% relative risk = 2.0 1 ; 95% confidence in- 
terval, 1.00-4.03). As expected [SI, EZ recipients had lower 
levels of measles hemagglutinin-inhibiting antibodies than recip- 
ients of standard Schwarz vaccine. All children had been vacci- 
nated against yellow fever in the past, and there was no differ- 
ence in antibody levels between groups. Though there was no 
difference overall, girls in the EZ group had a significantly 
higher neutralization ( P  = .012) or ELISA (P = .030) antibody 
response to rabies vaccine than girls in the standard vaccine 
group. There was no significant difference, overall or by sex, 
between the EZ and Schwarz groups with respect to lymphocyte 
counts or T cell subsets (FACScan; Be'cton Dickinson, Moun- 
tain View, CA). None of the children had a total CD4 cell count 
4 0 0  X 106/L or a CD4:CDS cell ratio of 4 . 5 .  There was no 
significant difference with respect to levels of neopterin (RIA; 
Henning, Berlin), serum albumin (standard colorimetric 
method), C-reactive protein (immunoturbidometric method; 
Hoffman La Roche, Basel, Switzerland), or retinol (high-perfor- 
mance liquid chromatography; Waters Associates, Milford, 
MA), delayed hypersensitivity to candida or PPD, or prevalence 
or density ofmalaria parasitemia. During the 2 years subsequent 
to the immunologic study, 2 children died, 1 in the EZ and 1 in 
the Schwarz group. 
The subsample included in the immunologic study appears to 
be representative of the children enrolled in the trial. We exam- 
ined antibody and cellular immune responses and found no 
meaningful differences. Apart from the expected difference in 
measles antibody levels [SI, the only significant difference was a 
higher antibody response to the rabies vaccine among EZ girls. 
There was no sign that either boys or girls in the EZ group had 
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Table 1. Clinical visits. mean immunologic and hematologic values. number of positive skin tests. and malaria parasitemia among 
recipients of high-titer EZ or standard-titer Schwarz measles vaccine, Niakhar. Senegal, 199 I .  
~~ ~~ ~ 
High-titer E2 Standard 
Total Girls Boys Total Girls Boys 
( n  = 69) ( n  = 32) ( n  = 37) ( n  = 67) ( n  = 31) (n  = 36) 
Conaultation. no. (".)* 30173 (41) 17/36 (47)t 13/37 (35) 22/70 (3  1 ) 8/34 (24) 14/36 (39) 
Antibodies 
Measles HAI* 5.0 (2.39)t 5.3 (2.46)t 4.6 (2.31)t 6.3 (2.07)t 6.6 (2.22)t 5.9 (1.91)+ 
Yellow fever' I .4 (0. 14) 1.6 (1.15) 1.3 (1.17) 1.4 (0.14) 1.8 (1.23) 1.0 (0.89) 
Rabies NT" 1.8 (0.34) 3.0 (0.25)t 2.7 (0.34) 2.8 (0.34) 2.8 (0.30)t 2.8 (0.37) 
Rshies ELISA. OD 4.0 (1.75) 4.6 ( 1.4S)t 3.4 ( I .78) 3.9 (1.53) 3.6 (1.71)i 4.0 (1.94) 
Total CD3 4703 (2203) 5074 (2642) 4365 ( 1682) 4483 (2296) 4192 (1712) 4752 (2734) 
Total CD4 2673 ( 1364) 2939 ( 1584) 2453 ( I  125) 2435 ( I  178) 2345 (877) 2513 (1393) 
Total CD8 1006 ( I  156) 2133 (1466) I900 (823) 1857 ( 1  119) 1751 (9091 1948 ( 1277) 
CD4:CD8 1.4 (0.6) 1.5 (0.5) 1.4 (0.6) 1.5 (0.5) 1.5 (0.5) 1.4 (0.5) 
Neopterin. log,, nmol/L 1.11 (0.32) 1.23 (0.32) 1.19(0.33) 1.20 (0.28) 1.22 (0.301 1.17 (0.27) 
Alhumin. g/L 40.4 (4.9) 40.9 (5.7) 39.9 (4,O) 39.8 (4.9) 39.5 (5.3) 40.1 (4.5) 
C-reactive protein 
Retinol. nmol/L 0.58 (0.70) 0.60 (O. 17) 0.56 (0.22) 0.60 (0.23) 0.59 (0.22) 0.60 (0.23) 
Candida 3 2  mm. no. 15/73 6/36 9/37 16/70 8/34 8/36 
PPD 2 2  mm. no. 5/73 4/36 1/37 2/70 1/34 1/36 
14/33 (42) 10136 (28) Parasitemia, no. (5.)' 28/70 (40) 11/34 (32) 17/36 (47) 24/69 (35) 
Density. log,dbL 3.8 (O. 15) 4.0 (0.59) 3.8 (0.88) 3.7 (0.22) 3.8 (0.97) 3.6 ( 1  2 3 )  
NOTE. 
* Children who had at least I consultation since age 10 months at health center or hospital. 
* Lug, measles hema~lutinin-inhibit ing (HAI) antibodies [SI. 
i Log, jellow fever neutralization antibodies. 
'1 Log,, rabies antibodies by reduction neutralization (NT) method. 
' Children with malaria pansites at time of tirst visit. 
Ljmphocytes X 10b/L 
Other hematologic values 
a5 mg/L. no. 11.38 3/15 8/13 9/39 3/15 6/24 
SAin tests 
Malsria 
Data are mean (SD) unless htated otherwise. 
P < .05. 
worse nutritional status. vitamin A deficiency. antibody re- 
sponse, or cellular immunity than those in the standard vaccine 
group. Thus. we have little evidence for long-term immunosup- 
pression. On the basis of data from Niakhar. it has been sug- 
gested that a persistently high mortality rate was associated with 
high-titer measles vaccine [5]. However, given the data from this 
and a similar study in Guinea-Bissau [6] ,  it is unlikely that there 
is an important immunosuppression persisting beyond 3 years of 
age among recipients of high-titer vaccines. Our study provided 
no clues for specific interventions that could correct a defined 
defect for girls in the EZ group. 
It is possible that those most affected had already died and 
that we were therefore not able to detect any important immuno- 
logic differences between the groups. However, the idea of a 
clinically important immunosuppression associated with high- 
titer vaccine [3, 71 finds little support in the fact that EZ vaccine 
is not associated with excess mortality in areas with low mortal- 
ity rates [7-91 and that in areas of high mortality [l-31, excess 
mortality is found only in comparison with standard Schwarz 
vaccination but not in comparison with unvaccinated children 
[ 1, 2.  1 O]. Studies of Peruvian children 2 years after immuniza- 
tion with high-titer EZ revealed a lower percentage of CD4 cells 
and reduced mitogen-induced lymphoproliferation responses 
than in children receiving low-titer vaccine [7]. In Guinea-Bis- 
sau [6], recipients of high-titer vaccine had no difference in CD4 
cell percentages or total CD4 cell counts but tended to have 
lower CD4:CD8 cell ratios than recipients of standard vaccine. 
These differences. though small in magnitude and within the 
range of normal values, were most consistently observed in girls 
[6, 71. In Senegal, we did not observe a reduction in CD4 cell 
percentage. in total CD4 lymphocyte count, or in CD4:CD8 cell 
ratio. It is unclear whether these observations are meaningfully 
related to the sex-specific differential mortality observed in sev- 
eral studies [ 1-31. Hence. we may need to look for other mecha- 
nisms to explain the differential mortality for girls receiving dif- 
ferent measles vaccines. 
Studies have suggested that Schwarz standard vaccine has a 
beneficial impact on survival that cannot be explained by con- 
trol of acute and long-term consequences of measles infection. 
and this effect may be particularly strong for girls [IO]. In this 
perspective. the reduced survival associated with high-titer EZ 
measles vaccine may be due not to a damaging effect of the 
vaccine but more to high-titer vaccine not having the same ben- 
eficial impact as standard Schwarz measles vaccine. 
r .I . I . . , ~ . . . . . . . . - ._ , 
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Disseminated Acyclovir-Resistant Herpes Simplex Virus 
Type 2 Treated Successfully with Foscarnet 
Colleagues-We describe a case of disseminated herpes sim- 
plex virus (HSV) type 2 infection in which a 22-year-old man 
developed multiple cutaneous lesions, organomegaly, hepatitis, 
and renal insufficiency. He was initially treated with intrave- 
nous (iv) acyclovir, but cultures of skin lesions demonstrated 
resistance to acyclovir. After he was switched to trisodium phos- 
phonoformate (foscarnet), his condition improved. We believe 
this to be the first reported case of acyclovir-resistant dissemi- 
nated HSV infection with acute hepatitis treated successfully 
with foscarnet in a patient without AIDS or organ transplanta- 
tion. 
Dissemination of an HSV infection is rare and usually occurs 
in organ (heart, liver, or kidney) [ 1,2] transplant patients and in 
those receiving medical treatment with steroids [3]. It also oc- 
curs in pregnant women [3], infants [4], and those with hemato- 
logic malignancies [5], chronic alcoholic liver disease [6], leuko- 
penia [I] ,  and thymic abnormalities [7], all of which depress 
cell-mediated immunity. Patients with compromised cell-me- 
diated immunity have more frequent and more severe infections 
with HSV [SI. 
Dissemination may be a complication of acute infection or 
reactivation of latent HSV [2]. Clinical presentations include 
fever and an early viral prodrome. The development of abdomi- 
nal pain, mucocutaneous vesicular eruptions, and lethargy often 
Informed consent was obtained from the patient for photography of the 
lesion. 
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follows the prodrome. Laboratory data show a left shift, fulmi- 
nant hepatic necrosis with elevation of aminotransferase, and a 
coagulopathy that may progress to disseminated intravascular 
coagulation [5]. Autopsy studies of subjects with disseminated 
HSV infections have shown organ involvement of the skin, liver, 
kidneys, adrenal glands, and respiratory and gastrointestinal 
tracts [2]. The mortality rate of those with HSV involvement of 
the liver is >SO% [ 11. 
The use of acyclovir prophylaxis in patients with recurrent 
local HSV infections or with more immunosuppressed condi- 
tions (e.g., AIDS and medical immunosuppression) are contrib- 
uting to the emergence of acyclovir-resistant strains of HSV [9]. 
These acyclovir-resistant strains can cause disseminated disease 
in immunosuppressed or immunocompetent patients. Acyclovir 
is dependent on viral thymidine kinase for phosphorylation and 
cellular enzymes for additional phosphorylation to its triphos- 
phorylated form, which inhibits viral DNA polymerase and 
therefore inhibits viral replication. Thymidine kinase-deficient 
or  -defective HSV strains have become more frequent in im- 
munocompromised patients and in those previously treated with 
acyclovir [9]. This resistance is due to selection of thymidine 
kinase-deficient or -defective virus strains that are unable to 
phosphorylate acyclovir. Foscarnet also inhibits viral DNA poly- 
merase, but it is not dependent on viral thymidine kinase or 
phosphorylation and is therefore effective against acyclovir-re- 
sistant HSV strains. 
We describe a 22-year-old patient who initially presented to 
his local emergency department with a 1 -  or 2-day history of 
dysuria and urethral discharge and increasing abdominal pain 
accompanied by anorexia and fatigue. He was found to have 
elevated serum aminotransferase levels. He was transferred to 
our institution for further evaluation. The patient had persistent 
fever following a viral prodrome and developed cutaneous le- 
sions (scalp, face, nares, palms, fingers, buttocks, perineum, and 
soles; figure 1). 
His medical history included aplastic anemia diagnosed in 
1988 and untreated myelodysplasia diagnosed in 1991. Al- 

